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Abstract: Visceral pain is very common and represents a major unmet clinical need for which
current pharmacological treatments are often insufficient. Tetrodotoxin (TTX) is a potent neurotoxin
that exerts analgesic actions in both humans and rodents under different somatic pain conditions,
but its effect has been unexplored in visceral pain. Therefore, we tested the effects of systemic TTX
in viscero-specific mouse models of chemical stimulation of the colon (intracolonic instillation of
capsaicin and mustard oil) and intraperitoneal cyclophosphamide-induced cystitis. The subcutaneous
administration of TTX dose-dependently inhibited the number of pain-related behaviors in all
evaluated pain models and reversed the referred mechanical hyperalgesia (examined by stimulation
of the abdomen with von Frey filaments) induced by capsaicin and cyclophosphamide, but not
that induced by mustard oil. Morphine inhibited both pain responses and the referred mechanical
hyperalgesia in all tests. Conditional nociceptor-specific Nav1.7 knockout mice treated with TTX
showed the same responses as littermate controls after the administration of the algogens. No motor
incoordination after the administration of TTX was observed. These results suggest that blockade of
TTX-sensitive sodium channels, but not Nav1.7 subtype alone, by systemic administration of TTX
might be a potential therapeutic strategy for the treatment of visceral pain.
Keywords: tetrodotoxin; visceral pain; referred mechanical hyperalgesia; TTX-sensitive voltage-gated
sodium channels; Nav1.7; capsaicin; mustard oil; cyclophosphamide
1. Introduction
Visceral pain is the pain originating from the internal organs caused by a variety of diseases; it the
most common form of pathological pain and represents a major reason for patients to seek medical
consultation [1–3]. However, despite its prevalence, the treatment of visceral pain is complex and the
current available pharmacological treatments have limited efficacy, therefore making it necessary to
develop effective drugs against this painful condition [4]. Visceral pain has unique characteristics that
differentiate it from somatic pain, which the response of visceral and somatic pain to drug treatment
different; however, most of our knowledge about pain mechanisms derives from experimental studies
of somatic rather than visceral pain [5–7]. In consequence, the mechanisms underlying visceral pain
Mar. Drugs 2017, 15, 188; doi:10.3390/md15060188 www.mdpi.com/journal/marinedrugs
Mar. Drugs 2017, 15, 188 2 of 13
are still poorly understood; however, the development of animal models of visceral pain is allowing
for the specific peripheral and central mechanisms involved to be investigated [8].
Tetrodotoxin (TTX) is a potent neurotoxin found in puffer fish and other marine animals that is
utilized as a defense against predators [9]. TTX is a selective blocker of voltage-gated sodium channel
(VGSCs) and it has been extensively used as a pharmacological tool to elucidate the role of VGSCs
in a wide range of physiological and pathophysiological processes in the nervous system [10,11].
VGSCs are typically classified according to their sensitivity to this toxin; thus, most of these sodium
channels (Nav1.1–1.4 and Nav1.6–1.7 subtypes) are blocked by nanomolar concentrations of TTX and
are defined as TTX-sensitive VGSCs, while others (Nav1.5 and Nav1.8–1.9) require higher (micromolar)
concentrations and are defined as TTX-resistant VGSCs [12].
It has been reported that TTX has analgesic and antihyperalgesic effects in several somatic pain
conditions, including nociceptive [13], inflammatory [13–15], muscle [16], and neuropathic [13,17–19]
pain models. In addition, TTX has been tested in humans in several clinical trials for counteracting
cancer-related pain [20,21] and pain resulting from chemotherapy (clinical trial NCT01655823) [22].
The antinociceptive properties of TTX are thought to be due to the stabilization of neuronal membranes
through the inhibition of Na+ ion flux required for initiation and propagation of nociceptive impulses,
especially in those pain conditions in which an upregulation of TTX-sensitive VGSCs in the peripheral
nervous system takes place [23].
As stated above, TTX has been tested with different degrees of efficacy in a variety of somatic
pain models. However, this neurotoxin, and in consequence the contribution of TTX-sensitive VGSCs
to visceral pain, has never been investigated in a pure visceral pain model. In the present study,
we have evaluated the antinociceptive effects of TTX in three different visceral pain models in
mice: the intracolonic administration of both capsaicin [24,25] and mustard oil [26,27] and a model
of cyclophosphamide-induced cystitis [27,28]. These models are viscero-specific and permit the
examination of both visceral pain and referred mechanical hyperalgesia to the abdominal wall, with this
latter feature being clinically very relevant and characteristic of visceral pain.
2. Results
2.1. Effect of Tetrodotoxin on Visceral Pain Induced by Chemical Stimulation of the Colon
To evaluate the effect of TTX on pure visceral pain, we used two common models: the intracolonic
instillation of capsaicin and mustard oil. The intracolonic administration of capsaicin and mustard
oil vehicle elicited a small and a moderate number of abdominal licking behaviors, respectively
(Figure 1A,B). By contrast, the intracolonic instillation of capsaicin (1%) and mustard oil (0.1%) evoked
a greater number of multiple types of pain-related behaviors (e.g., licking, stretching, and contraction
of the abdomen) in control animals (Figure 1A,B). The subcutaneous (s.c.) administration of TTX
(1–6 µg/kg) 30 min before the intracolonic instillation of capsaicin (1%) significantly reduced the
number of pain-related responses in a dose-dependent manner (Figure 1A). Similarly, the s.c. treatment
with TTX (3 and 6 µg/kg) dose-dependently ameliorated the number of pain-related responses induced
by intracolonic mustard oil (Figure 1B). As a control analgesic drug, we used morphine (8 mg/kg, s.c.),
which fully abolished the pain-related behaviors produced by capsaicin and mustard oil, even below
those observed in the vehicle + saline group (Figure 1A,B).
The intracolonic administration of capsaicin (1%) and mustard oil (0.1%) also produced a strong
referred mechanical hyperalgesia in the saline-treated group, as it decreased the mechanical threshold
in those mice, with respect to naïve mice (represented with a dashed line) (Figure 1C,D). In contrast,
the vehicles of both algogens produced a slight reduction of the mechanical threshold in the
saline-treated animals (Figure 1C,D). The s.c. injection of TTX (1–6 µg/kg) also reversed the mechanical
hypersensitivity induced by capsaicin in a dose-dependent manner, abolishing it completely with
the dose of 6 µg/kg (Figure 1C). However, TTX (3 and 6 µg/kg, s.c.) was completely ineffective on
the mechanical referred hyperalgesia induced by intracolonic mustard oil at any of the doses tested
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(Figure 1D). As expected, morphine (8 mg/kg, s.c.) reversed the referred hyperalgesia in both models,
even above the values of naïve mice (Figure 1C,D).
In summary, TTX was able to decrease the number of pain-related behaviors produced by the
intracolonic administration of both capsaicin and mustard oil. However, whereas TTX reversed the
mechanical referred hyperalgesia produced by capsaicin, it had no effect on the mechanical referred
hyperalgesia in the mustard oil model.
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indicates  the  50%  threshold  force  in  naïve WT mice.  Each  bar  and  vertical  line  represents  the   
mean ± SEM of values obtained in at least eight animals per group. Statistically significant differences 
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Figure 1. Effects of tetrodotoxin (TTX) and morphine on the pain-related behaviors (A,B) and the
referred mechanical hyperalgesia (C,D) induced by intracolonic administration of capsaicin 1% and
mustard oil 0.1% in wild-type (WT) mice. The subcutaneous (s.c.) administration of the drugs or
their solvent (saline) was performed 30 min before the intracolonic administration of the algogens or
their vehicles. Behavioral pain responses were recorded during the first 20 min after the intracolonic
instillation. The referred mechanical hyperalgesia (evaluated by stimulation of the abdomen with von
Frey filaments) was measured 20 min after the instillation. The dashed line in (C,D) graphs indicates
the 50% threshold force in naïve WT mice. Each bar and vertical line represents the mean± SEM of values
obtained in at least eight animals per group. Statistically significant differences between the values
obtained in drug- and saline-injected mice treated with the algogen: * p < 0.05; ** p < 0.01 (one-way
ANOVA followed by Bonferroni test).
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2.2. Effect of Tetrodotoxin on Cyclophosphamide-Induced Visceral Pain
To test the effect of TTX on the pain originating in a different visceral organ, we used the model of
bladder pain/cystitis induced by cyclophosphamide. The solution of cyclophosphamide (100 mg/kg)
was administered intraperitoneally (i.p.) and produced a progressive development of visceral pain
behaviors. Mice treated with cyclophosphamide showed a significantly higher painful score than
mice treated with the vehicle (Figure 2A). The s.c. administration of TTX (3 and 6 µg/kg) significantly
reduced this pain-related score in a dose-dependent manner, but none of them were enough to
completely abolish the pain responses (Figure 2A). The control drug, morphine (8 mg/kg, s.c.),
highly reduced the pain score, but it was also unable to eliminate the pain responses (Figure 2A).
The cyclophosphamide vehicle (saline i.p.) barely provoked pain-related responses in the evaluated
animals (Figure 2A).
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Figure 2. Effects of TTX and morphine on the pain-related behaviors (A) and the r ferr d mechanical
hyperalgesia (B) induced by the i.p. administration of cyclophosphamide (100 mg/kg) in WT mice.
The s.c. administration of the drugs or their solvent (saline) was performed 2 h after the administration
of cyclophosphamide or its vehicle. Behavioral score was recorded at 30 min intervals over the
150–240 min observation period after the injection of cyclophosphamide or its vehicle. The referred
mechanical hyperalgesia (evaluated by stimulation of the abdomen with von Frey filaments) was
measured at 240 in after cyclophosphamide or its vehicle injection. The dashed line in (B) graph
indicates the 50% threshold force in naïve WT mice. Each bar and vertical line represents the mean± SEM
of values obtained in at least eight animals per group. Statistically significant differences between the
values obtained in drug- and saline-injected mice treated with cyclophosphamide: * p < 0.05; ** p < 0.01
(one-way ANOVA followed by Bonferroni test).
On the mechanical threshold, animals administered with the cyclophosphamide vehicle showed
similar values as naïve mice (Figure 2B). However, mice showed a marked reduction on their
mechanical thresholds with respect to naïve (dashed line) and cyclophosphamide vehicle-injected
animals when they were tested 4 h after cyclophosphamide treatment (Figure 2B). The treatment with
TTX (3 and 6 µg/kg, s.c.) reversed in a dose-dependent manner the mechanical referred hyperalgesia
evoked by cyclophosphamide with respect to saline-injected mice but did not produce a complete
recovery (Figure 2B). Morphine administration fully reversed the referred mechanical hyperalgesia
and produced a pronounced analgesic effect (Figure 2B).
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2.3. Effect of Tetrodotoxin in Nav1.7 Knockout Mice
To study the possible involvement of the sodium channel Nav1.7 in the visceral pain models
tested, we used conditional Nav1.7 knockout mice (KO-Nav1.7), which possess a specific ablation
of these channels in Nav1.8-positive neurons. These animals, treated with saline s.c., did not show
any differences in pain-related responses and referred hyperalgesia with respect to their control mice
littermates when they were instilled intracolonically with capsaicin and mustard oil (Figure 3A left panel)
or treated i.p. with cyclophosphamide (Figure 3A right panel). When the maximum dose of TTX used
(6 µg/kg, s.c.) was administered in KO-Nav1.7 mice in the different pain models, we also did not find
a difference between both types of animals, and TTX reversed both the pain responses and the referred
hyperalgesia in the same way that it did in the control animal littermates (Figure 3A,B). These results
indicate that Nav1.7 in sensory neurons expressing nociceptive markers is not necessary for the effect
of TTX.
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Figure 3. Comparison of the effects of TTX (6 µg/kg) and saline (0) on the pain-related behaviors
(A) and the referred mechanical hyperalgesia (B) in WT and KO-Nav1.7 mice. TTX or saline was
injected s.c. 30 min before the instillation of capsaicin and mustard oil and 2 h after the administration
of cyclophosphamide. Pain responses were recorded during the first 20 min after the intracolonic
instillation of capsaicin and mustard oil (A, left panel) and over the 150–240 min observation period
after the injection of cyclophosphamide (A, right panel). (B) Referred mechanical hyperalgesia was
measured 20 min after the instillation of the algogens and 4 h after the cyclophosphamide injection.
Each bar and vertical line represents the mean ± SEM of values obtained in at least eight animals per
group. Statistically significant differences between the values obtained in TTX- and saline-injected
mice: ** p < 0.01 (one-way ANOVA followed by Bonferroni test).
2.4. Tetrodotoxin Does Not Alter Locomotor Coordination
Animals treated with TTX and morphine were tested with a rotarod device to detect effects on
the motor coordination of the mice. We tested the highest dose of TTX used in the pain experiments
(6 µg/kg, s.c.). The latency period to fall from the rotarod apparatus before the treatment with TTX,
morphine, or saline (time 0) was very similar in all groups. The rotarod latency time values during
all the evaluation periods following the administration of saline or TTX (6 µg/kg, s.c.) were not
significantly different from the baseline values (time 0) and there were no differences between the
rotarod values of mice treated with saline and TTX at any time after administration (Figure 4). Similarly,
animals treated with morphine (8 mg/kg, s.c.) showed no motor incoordination and even induced
higher values in the rotarod test after 120 min in comparison to their own values at time 0 (Figure 4).
Therefore, TTX did not induce any locomotor disturbing effect.
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Figure 4. Effects of TTX, morphine, and saline on the rotarod test. The latency time to fall down from
the rotarod apparatus was recorded in each mouse before (time 0) and 30, 60, and 120 min after the s.c.
injection of the drugs or saline. Each point and vertical line represent the mean ± S.E.M. of the values
obtained in at least eight animals per group. Statistically significant differences between the values at
time 0 and time 120 min after the s.c. injection of morphine: ** p < 0.01 (two-way repeated measures
ANOVA followed by Bonferroni test).
3. Discussion
This is the first report detailing the actions of systemic TTX in pure visceral pain models. The main
findings were that TTX administration reduced both the pain responses and the referred mechanical
hyperalgesia in colonic and cystitis pain models, and that the TTX-sensitive channel Nav1.7 was not
involved in those effects.
First, our results show that the s.c. administration of TTX at the doses tested (1–6 µg/kg) herein
ameliorated the visceral pain. These doses of TTX were chosen based on the literature and previous
studies showing safety and lack of toxicity [13,17]. In mice, the toxicity of TTX depends on the route of
administration, and the reported lethal values after s.c. administration of TTX were 12.5–16 µg/kg
and 8–10 µg/kg for the lethal dose LD50 and the minimal lethal dose, respectively [29,30]. We found
no signs of toxicity or motor incoordination in the rotarod test after the administration of the highest
dose tested. These results are in agreement with previous data on the rotarod test using mice [17] and
rats [18].
TTX has been tested before in the acetic acid-writhing test where it significantly reduced the
number of abdominal contractions [13]. This test is a widely considered model of inflammatory
and visceral pain, although this irritant combines visceral and somatic mechanisms of peritoneal
pain [26] and exhibits a lack of pharmacological specificity (i.e., non-analgesic drugs can inhibit the
writhings) [31]. Also, this model generates only brief acute reactions and does not reproduce any
clinically relevant condition of visceral pain observed in humans such as the referred pain to the
abdominal wall. By contrast, the animal models used in the present study permit exploration of
both visceral pain-related responses and referred hyperalgesia, so they are considered appropriate
translational models of visceral pain. In particular, the intracolonic capsaicin model in mice resembles
the responses observed in a human experimental model after the application of capsaicin to the
human gut [32–34]. The cyclophosphamide cystitis in rodents derives from the observation of the
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human patients treated with this anti-tumoral agent, thus it similarly mimics a human visceral pain
condition [35].
We found in our study that TTX dose-dependently inhibited the number of pain-related
behaviors in both colonic models (capsaicin 1% and mustard oil 0.1%) but only reversed the referred
mechanical hyperalgesia induced by intracolonic capsaicin. The pain responses induced by intracolonic
capsaicin and mustard oil are attributable to the direct stimulation of colonic nociceptors [26,36].
Thus, the spontaneous pain behaviors induced by capsaicin and mustard oil are sustained by ongoing
activity in nociceptors sensitized by the initial application of the irritants and, as such, can be partially
considered as acute pain responses. It has been shown that systemic administration of TTX had no
effect on somatic acute pain induced by thermal, mechanical, or chemical stimuli [23]. Apart from
the results in the acetic acid test, to our knowledge, the effect of TTX has only been tested in one
model of chemical pain, the formalin test [13]. The formalin test is a commonly used animal model
and comprises a first phase (acute pain) driven by nociceptor activation followed by a second phase
associated with inflammation and spinal cord hypersensitivity [37]. In this test, Marcil and coworkers
found that TTX had no effect in the early or acute phase but decreased the pain scores in the second
phase in rats. The early phase of the formalin test occurs typically in the first 5 min and the second phase
starts from 10 to 15 min and lasts about 40–60 min after the injection [31]. In our study, the intracolonic
capsaicin- and mustard oil-induced responses were evaluated for a time period much longer (20 min)
than that of acute pain induced by intraplantar formalin (5 min) and, therefore, TTX might be acting
in an inflammatory or sensitized pain state. In fact, TTX has previously been shown to reduce the
pain behaviors in the second phase of the formalin test and the mechanical hyperalgesia induced by
carrageenan in rats [13,15]. In any case, there are no reported results of TTX in spontaneous/acute pain
models using chemical stimulus in mice to compare with our results, and further studies in somatic
pain could help to clarify this issue.
In contrast to the pain-related behaviors data, s.c. administration of TTX only reversed the
referred mechanical hyperalgesia induced by intracolonic capsaicin but had no effect on the mustard
oil-induced referred pain. Besides the inflammation pain models (i.e., formalin and carrageenan tests),
the actions of TTX in pain hypersensitivity have been previously documented in somatic pain models [23].
In particular, the reduction of mechanical hypersensitivity induced by intraplantar capsaicin [38] and
the neuropathic pain responses induced by mechanical stimulation [17,19] have been well established.
Thus, the inhibition of the mechanical referred pain induced by intracolonic capsaicin is in agreement
with previous reports showing that TTX exerts antihyperalgesic effects in rodents [23].
Regarding the inability of TTX to inhibit the referred hyperalgesia in response to intracolonic
mustard oil, there are differences between the two irritants that could explain this differential effect.
Both compounds activate different subtypes of the transient receptor potential (TRP) channel family,
notably capsaicin is a TRPV1 agonist whereas mustard oil is a TRPA1 agonist [39]. Thus, the differential
effects of TTX against the referred mechanical hyperalgesia induced by these compounds may be
related with the differential noxious activation via TRPV1 or TRPA1. However, it has been shown
that mustard oil activates TRPV1 in nociceptive neurons, supporting the role of TRPV1 as a direct
mediator of mustard oil-induced irritation [40]. Since TTX reverses the referred hyperalgesia induced
by capsaicin through TRPV1 stimulation, and mustard oil also activates this channel, TTX might inhibit
the mustard oil-induced referred hyperalgesia, but this has not been observed in our study. Another
possible explanation of this lack of effect of TTX in reversing the hyperalgesia evoked by mustard oil
may be related with the differential severity or type of the injury caused by both algogens. Although
the intracolonic administration of either capsaicin or mustard oil evoked similar referred hyperalgesia
in control animals, mustard oil produces direct tissue damage and a very pronounced inflammatory
response, whereas capsaicin evokes a pure neurogenic inflammation [26,41]. Thus, it could be possible
that the type of lesion generated by each irritant can influence the antihyperalgesic efficacy of TTX.
Previous studies have reported that the administration in mice of the nonsteroidal anti-inflammatory
drug ketoprofen suppresses the pain-related behaviors but not the referred pain after intracolonic
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mustard oil [42], whereas ketoprofen was reported to have no effect in either type of pain after
the instillation of capsaicin [24]. By contrast, morphine was able to inhibit pain behaviors and
referred hyperalgesia after the intracolonic administration of both mustard oil and capsaicin in these
studies [24,42]. These results indicate that the same drug can exert distinct efficacy for alleviating
visceral pain depending on the algogen used and the pain responses recorded. Taken together, along
with our data, it seems likely that the difference in the antihyperalgesic efficacy of TTX might be due
to the damage produced by mustard oil compared to capsaicin.
TTX reduced the behavioral pain score and the referred mechanical hyperalgesia induced
by the systemic administration of cyclophosphamide. Cyclophosphamide produces cystitis by
gradual accumulation of a toxic metabolite (acrolein) in the bladder, and thus is a model of tonic
noxious chemical stimulation and inflammatory visceral pain [35]. After the administration of
cyclophosphamide, the acrolein accumulates during the 4 h of observation, and this slow accumulation
is accompanied by a progressive increase in pain behaviors and a considerable bladder inflammation.
As mentioned above, it was previously reported that TTX plays a role in reducing inflammatory pain
in somatic pain models. Here, TTX was injected 2 h after the cyclophosphamide and the behavioral
pain score was recorded during the next 2 h, hence, the effect of TTX in this model could be associated
with its proved capacity to attenuate somatic inflammatory pain. Furthermore, cyclophosphamide
also induces a neurogenic inflammation and sensitization [41]. Therefore, the antihyperalgesic effect
of TTX in this model is consistent with the reduction of the referred hyperalgesia observed after the
intracolonic capsaicin since it also induces a neurogenic inflammation.
According to previous studies, morphine totally abolished the spontaneous pain and induced
a clear analgesic effect on the referred pain (i.e., evoked a much higher threshold than that observed in
naïve animals) in both capsaicin [24] and mustard oil models [26]. Also, the responses and mechanical
hyperalgesia were greatly attenuated in the cyclophosphamide model after the administration of
morphine, as was previously reported [28]. Consequently, these results suggest that all types of
behaviors evaluated were pain-related.
Since we administered TTX systemically, the present effects can be peripherally or centrally
mediated. Our data in the rotarod test indicate that TTX did not affect the central nervous system, thus
suggesting a peripheral action. Also, a higher concentration (8 µg/kg) than that used here did not alter
the contralateral paw withdrawal responses in a burn wound pain model in rat [43], supporting a lack
of central effects. In addition, TTX is a hydrophilic compound which barely crosses the blood-brain
barrier, thus entry to the central nervous system is limited [29], and we have previously reported
peripheral effects using the same doses of TTX (1–6 µg/kg) in a model of neuropathic pain induced
by paclitaxel [17]. Accordingly, the inhibition of pain responses and antihyperalgesic effects of TTX
observed in the present study might be interpreted through peripheral actions.
The effects of TTX in the present study could be attributable to one or several TTX-sensitive VGSCs
such as Nav1.1, Nav1.2, Nav1.3, Nav1.4, Nav1.6, and Nav1.7. However, our data using a conditional
nociceptor-specific Nav1.7 knockout mouse (KO-Nav1.7) suggest that subtype Nav1.7 expressed in
Nav1.8 positive neurons is not fully required for visceral pain. In agreement with this finding, it has
been recently reported that Nav1.7 does not play a role in visceral pain and that these KO-Nav1.7 mice
have lost almost all visceral sensory neurons [27]. Then, the actions of TTX herein must be theoretically
mediated by one or more different VGSCs subtypes, since the highest dose administered (6 µg/kg)
evoked the same responses in both KO-Nav1.7 and littermate controls. Moreover, the application of
TTX did fully block afferent firing to noxious phasic distension in KO-Nav1.7 mice [27]. Nevertheless,
we cannot discard the possibility that some Nav1.7-positive neurons lacking Nav1.8 expression remain
active, which may be enough to sustain pain responses. Among the remaining TTX-sensitive subtypes,
Nav1.3 has been proposed to play a role in pain, although contradictory data between several animal
studies have been published [23,44,45]. Nav1.6 [46–48] and Nav1.1 [49] have also been reported to
play a role in several pain conditions including visceral pain. Nav1.2 is abundantly expressed in the
adult central nervous system but does not seem to be involved in pain, whereas Nav1.4 is almost
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restricted to the skeletal myocyte [23,45]. All these TTX-sensitive VGSCs have been found to be present
in significant proportions (except for Nav1.4, which showed very low expression) in lumbosacral and
thoracolumbar colonic sensory neurons in mice [27]. However, we cannot determine whether the effect
of TTX was produced by the blockade of one or various of these TTX-sensitive subtypes, and further
research is needed to elucidate this issue.
In summary, our data indicate that systemic administration of TTX could have a potential
therapeutic use for treating clinical visceral pain, since the animal pain models used herein have
translational value and they have been validated in humans.
4. Materials and Methods
4.1. Animals
Adult wild-type (WT) and conditional nociceptor-specific Nav1.7 knockout (KO-Nav1.7) mice
of either sex weighing 20–30 g were used. The KO-Nav1.7 and their littermate controls were bred at
the Biomedical Research Center (University of Granada), were maintained on a C57Bl/6 background,
and were generated as described previously [50]. Animals were housed in colony cages in temperature
and light-controlled rooms (22 ± 1 ◦C, lights on at 08.00 h and off at 20.00 h, air replacement every
20 min). A standard laboratory diet (Harlan Teklad Research diet, Madison, WI, USA) and tap water
were available ad libitum until the beginning of the experiments. Testing took place during the
light phase (from 09.00 h to 15.00 h). Mice were handled in accordance with international standards
(European Communities Council directive 2010/63), and the study was approved by the Research
Ethics Committee of the University of Granada.
4.2. Drugs and Drug Administration
The drugs used were the voltage-gate sodium channels (VGSCs) blocker tetrodotoxin (TTX)
(Tocris Cookson Ltd, Bristol, UK) and the µ-opioid receptor agonist morphine hydrochloride (General
Directorate of Pharmacy and Drugs, Spanish Ministry of Health, Madrid, Spain), which was used
as a control drug. Both drugs were dissolved in sterile physiological saline before the start of the
experiments, and 5 mL/kg of the drug or its solvent was injected subcutaneously (s.c.).
The algogens administered were capsaicin, mustard oil, and cyclophosphamide, and the
concentrations/doses used were chosen according to previous data of our group [24,27]. Capsaicin
(Sigma-Aldrich, Barcelona, Spain) was prepared to make up a 1% (w/v) stock solution in
a vehicle containing 10% absolute ethanol (Panreac Química SA, Barcelona, Spain), 10% Tween 80
(Sigma-Aldrich, Barcelona, Spain), and 80% sterile saline. This capsaicin solution was prepared once
a week and stored at −20◦C in aliquots which were used on the day of the experiment. Mustard oil
(Sigma-Aldrich, Barcelona, Spain) was dissolved in 70% ethanol (Sigma-Aldrich, Barcelona, Spain) and
30% sterile saline and prepared at 0.1%. The capsaicin or mustard oil solutions (50 µL) were instilled
into the colon by introducing through the anus a fine round-tip cannula (external diameter 0.61 mm;
4 cm long) connected to a 1710 TLL Hamilton microsyringe (Teknokroma, Barcelona, Spain). Control
animals were intracolonically instilled with the same volume of vehicle.
Cyclophosphamide 100 mg/kg (Sigma-Aldrich, Barcelona, Spain), which was used to induce
cystitis, was dissolved in saline and injected intraperitoneally (i.p.) at the volume of 10 mL/kg. Control
animals were injected i.p. with the same volume of saline.
Each animal was used only once and received a single concentration of algogen (or its vehicle)
and a single dose of one drug (or saline). All experimental groups were run in parallel and the
experimenters were blind to the pharmacological treatment and the genotypes of the animals.
4.3. General Procedures for Evaluating Intracolonic Visceral Pain
Pain-related behaviors and referred mechanical hyperalgesia were assessed using previously
described methods [24,26]. Animals were habituated for 40 min in individual transparent plastic
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boxes (7 × 7 × 13 cm) on an elevated platform with a wire mesh floor. After the habituation period,
animals were s.c. injected with the drug or saline 30 min before the intracolonic administration of
50 µL capsaicin (1%), mustard oil (0.1%), or vehicles. Petroleum jelly was applied on the perianal area
to prevent stimulation of somatic areas. The animal was returned back to the chamber, and the number
of pain-related behaviors (licking of abdomen, stretching of abdomen, and abdominal retractions) was
counted for 20 min.
After the evaluation of the spontaneous pain behaviors, we tested the presence of referred
hyperalgesia by measuring the withdrawal response to a mechanical stimulation of the abdomen at
20 min after the algogen administration (or its vehicle). A series of calibrated von Frey filaments
(0.02–2 g; Touch-Test Sensory Evaluators, North Coast Medical Inc., Gilroy, CA, USA) were
applied to the abdomen using the up-down paradigm [51]. Filaments were applied three times
for 2–3 s, concentrating the stimulation on the lower and mid abdomen, and avoiding perianal and
external genitalia areas, as previously reported [24,26]. Each test started with the application of the
0.4-g filament.
4.4. Procedure for Evaluating Cyclophosphamide-Induced Cystitis
In a separate set of experiments, cyclophosphamide-evoked visceral pain and referred
hyperalgesia were examined following a previously described protocol [27,35]. After a 40-min
habituation period, mice were injected intraperitoneally with cyclophosphamide (100 mg/kg) or
saline. Drugs or saline were s.c. injected 2 h after the cyclophosphamide injection and the pain
behaviors manifested by the animals were recorded for 2 min every 30 min over a 2 h observation
period. The recorded pain-related behaviors were coded according to the following scale: 0 = normal,
1 = piloerection, 2 = strong piloerection, 3 = labored breathing, 4 = licking of the abdomen,
and 5 = stretching and contractions of the abdomen [27]. If more than one of these pain behaviors was
observed in one period, the sum of the corresponding points to the different types of behaviors was
assigned; i.e., if two stretching and contractions (5 points each) and one abdominal licking (4 points)
occurred during an observation period, the final score was 9 instead of 14 points. An overall score was
obtained by summing the scores assigned at each time point. At the end of the 2 h observation period
(i.e., 4 h after the cyclophosphamide injection), the referred mechanical hyperalgesia was determined
using the von Frey filaments as described in the previous section.
4.5. Rotarod Test
Alterations in motor coordination were assayed with a mouse rotarod device (Ugo Basile, Comerio,
Italy) as previously described [52]. The rotarod apparatus was set to accelerate from 4–40 rpm over
5 min. Three training sessions separated by 30-min intervals were performed 1 day before drug testing.
Rotarod latencies were measured before the administration of the drugs or saline (time 0) and 30, 60,
and 120 min after treatment. A 300-s cut-off time was established in all experiments.
4.6. Data Analysis
Differences between the values were compared across experimental groups with one-way or
two-way analysis of variance (ANOVA), as indicated in the figure legends, followed by the Bonferroni
test, using the Prism 5 program (Graphpad Inc., La Jolla, CA, USA). The differences between means
were considered statistically significant when p < 0.05.
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